Palisade Bio (NASDAQ:PALI) Stock, Quote.Headers.trade-ideas

Palisade Bio

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

PALI

Biotech

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

Palisade Bio progresses its Phase 1 study for PALI-2108, showing safety and targeted bioactivation, with topline data anticipated in early 2025.

What&#39;s Going On With Palisade Bio Stock On Thursday?

jobless shutter

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

GOEV

KROS

SPGC

TFFP

TRVI

Nasdaq Down 50 Points; US Initial Jobless Claims Rise

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

ABSI

ADBE

AMPG

AVGR

BCTX

BURU

COEP

CTHR

CTNM

DBVT

FRST

NEHC

NIVF

RZLV

SFHG

WHLR

Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Palisade Bio Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

Paliburg Holdings Ltd

PALISADES GOLDCORP LTD by PALISADES GOLDCORP LTD.

Palisades Goldcorp Ltd

Press Releases

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Events

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

Palisade Bio, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio Participates in Virtual Investor "What This Means" Segment

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

AKTX

AMIX

AREC

CNSP

HURA

NVNO

OTLK

Alzamend Neuro

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Entero Therapeutics

Genprex

GRI Bio

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Synaptogenix

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Brookline Capital

Maxim Group

Ladenburg Thalmann

Comments

Palisade Bio

Palisade Bio (NASDAQ:PALI) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga